Efficacy, Safety, and in vitro Sensitivity of Omadacycline in the Treatment of Brucellosis: A Case Series Study
Abstract
Purpose: Treatment options for brucellosis are limited. Omadacycline demonstrates strong antibacterial activity against a broad spectrum of bacteria. However, the efficacy of omadacycline against Brucella spp. remains unclear.
Patients and methods: We screened brucellosis patients who received omadacycline from April to July 2023 across five hospitals in China and conducted in vitro experiments to evaluate the activity of omadacycline against different Brucella species.
Results: A total of 13 patients were included, all of whom received omadacycline as part of a combination regimen. Within this cohort, 11 were diagnosed with Brucella spondylitis, and 8 of these underwent surgical intervention. Omadacycline was administered as second-line therapy in 10 (76.9%) patients due to uncontrolled symptoms and as empirically in the remaining 3. Following the initiation of an omadacycline-containing regimen, symptoms of fever and/or back pain improved rapidly, regardless of whether it was used as empirical or second-line therapy. The median time from omadacycline initiation to defervescence was 3 days, and to relief of back pain was 7 days. The median duration of omadacycline treatment was 32 days, and it was administered in combination with other agents, including rifampicin and cephalosporins. The regimen was well tolerated, with only one patient experiencing mild nausea. In vitro, omadacycline demonstrated consistent activity against all tested Brucella species.
Conclusion: In this…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 13 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.